These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 10726623)

  • 41. Tissue polypeptide-specific antigen and CA 125 as serum tumor markers in ovarian carcinoma.
    Shabana A; Onsrud M
    Tumour Biol; 1994; 15(6):361-7. PubMed ID: 7997808
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Combining a symptoms index with CA 125 to improve detection of ovarian cancer.
    Andersen MR; Goff BA; Lowe KA; Scholler N; Bergan L; Dresher CW; Paley P; Urban N
    Cancer; 2008 Aug; 113(3):484-9. PubMed ID: 18615684
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The role of ultrasound and tumour markers in the early detection of ovarian cancer.
    Oram DH; Jeyarajah AR
    Br J Obstet Gynaecol; 1994 Nov; 101(11):939-45. PubMed ID: 7999723
    [No Abstract]   [Full Text] [Related]  

  • 44. Assessment of the clinicopathological relevance of mesothelin level in plasma, peritoneal fluid, and tumor tissue of epithelial ovarian cancer patients.
    Okła K; Surówka J; Frąszczak K; Czerwonka A; Kaławaj K; Wawruszak A; Kotarski J; Wertel I
    Tumour Biol; 2018 Oct; 40(10):1010428318804937. PubMed ID: 30319054
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Studies on angiogenesis in the benign and malignant ovarian neoplasms with the use of color and pulsed Doppler sonography and serum CA-125, CA-19.9, CA-72.4 and vascular endothelial growth factor measurements.
    Czekierdowski A
    Ann Univ Mariae Curie Sklodowska Med; 2002; 57(1):113-31. PubMed ID: 12898913
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Coordinate elevation of serum markers in ovarian cancer but not in benign disease.
    Bast RC; Knauf S; Epenetos A; Dhokia B; Daly L; Tanner M; Soper J; Creasman W; Gall S; Knapp RC
    Cancer; 1991 Oct; 68(8):1758-63. PubMed ID: 1913520
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Use of tumour markers in monitoring the course of ovarian cancer.
    Rustin GJ; Nelstrop AE; Bentzen SM; Piccart MJ; Bertelsen K
    Ann Oncol; 1999; 10 Suppl 1():21-7. PubMed ID: 10219449
    [TBL] [Abstract][Full Text] [Related]  

  • 48. New technologies for the identification of markers for early detection of ovarian cancer.
    Bandera CA; Ye B; Mok SC
    Curr Opin Obstet Gynecol; 2003 Feb; 15(1):51-5. PubMed ID: 12544502
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Significance of preoperative serum CA-125 levels in the prediction of lymph node metastasis in epithelial ovarian cancer.
    Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
    Acta Obstet Gynecol Scand; 2008; 87(11):1136-42. PubMed ID: 18951217
    [TBL] [Abstract][Full Text] [Related]  

  • 50. New tumor markers: CA125 and beyond.
    Bast RC; Badgwell D; Lu Z; Marquez R; Rosen D; Liu J; Baggerly KA; Atkinson EN; Skates S; Zhang Z; Lokshin A; Menon U; Jacobs I; Lu K
    Int J Gynecol Cancer; 2005; 15 Suppl 3():274-81. PubMed ID: 16343244
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Preoperative prediction of optimal resectability in advanced ovarian cancer using CA-125.
    Berek JS
    Gynecol Oncol; 2000 May; 77(2):225-6. PubMed ID: 10785468
    [No Abstract]   [Full Text] [Related]  

  • 52. Preoperative CA 125: an independent prognostic factor in patients with stage I epithelial ovarian cancer.
    Nagele F; Petru E; Medl M; Kainz C; Graf AH; Sevelda P
    Obstet Gynecol; 1995 Aug; 86(2):259-64. PubMed ID: 7617357
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Preoperative assessment of ovarian tumors using a modified multivariate index assay.
    Abdurrahman HA; Jawad AK; Alalalf SK
    J Ovarian Res; 2018 May; 11(1):41. PubMed ID: 29843758
    [TBL] [Abstract][Full Text] [Related]  

  • 54. CA 125 half-life and CA 125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome: results of a French multicentric study.
    Riedinger JM; Wafflart J; Ricolleau G; Eche N; Larbre H; Basuyau JP; Dalifard I; Hacene K; Pichon MF
    Ann Oncol; 2006 Aug; 17(8):1234-8. PubMed ID: 16766592
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Ca-125 in diagnosis and monitoring of patients with ovarian cancer].
    Bocheva Y; Bochev P; Ivanov S
    Akush Ginekol (Sofiia); 2015; 54(1):11-7. PubMed ID: 25909124
    [TBL] [Abstract][Full Text] [Related]  

  • 56. TPS and CA 125 levels in serum, cyst fluid and ascites of patients with epithelial ovarian neoplasms.
    Harłozinska A; Sedlaczek P; Van Dalen A; Rozdolski K; Einarsson R
    Anticancer Res; 1997; 17(6D):4473-8. PubMed ID: 9494553
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Preoperative measurement of serum C-reactive protein: is it useful in the differential diagnosis of adnexal masses?
    Yoshida A; Derchain SF; Pitta DR; Crozatti N; Andrade LALA; da Silva RF; Sarian LO
    Int J Biol Markers; 2017 Mar; 32(1):e83-e89. PubMed ID: 27516000
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical significance of the tumour markers CA 125 II and CA 72-4 in ovarian carcinoma.
    Hasholzner U; Baumgartner L; Stieber P; Meier W; Reiter W; Pahl H; Fateh-Moghadam A
    Int J Cancer; 1996 Aug; 69(4):329-34. PubMed ID: 8797878
    [TBL] [Abstract][Full Text] [Related]  

  • 59. New method: Are tumor markers in vaginal-washing fluid significant in the diagnosis of primary ovarian carcinoma?
    Terzi H; Kale E; Kale A; Turkay U; Chong GO; Lee YS
    Eur J Gynaecol Oncol; 2015; 36(5):560-3. PubMed ID: 26513883
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Results from an ultrasound-based familial ovarian cancer screening clinic: a 10-year observational study.
    Tailor A; Bourne TH; Campbell S; Okokon E; Dew T; Collins WP
    Ultrasound Obstet Gynecol; 2003 Apr; 21(4):378-85. PubMed ID: 12704748
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.